Published in Drug Law Weekly, August 25th, 2009
The agreement marks the end of all pending litigations filed and consolidated since 2006 in the U.S. District Court for the District of New Jersey against several generic drug manufacturing companies that had sought approval to market solid oral dosage forms of desloratadine products in the United States as generic brands prior to the expiration of certain Schering Corporation patents.
This agreement resolves all pending...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2009-08-25)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.